Pharmacoevidence Private
Pharmacoevidence Private, a leading name in the pharmacoeconomic and health outcomes research industry, is headquartered in India. Established in 2012, the company has rapidly expanded its operational reach across major regions, including North America and Europe. Specialising in evidence-based solutions, Pharmacoevidence offers a unique blend of health technology assessment, real-world evidence generation, and market access strategies tailored to the pharmaceutical and healthcare sectors. With a commitment to enhancing patient outcomes and optimising healthcare resources, the company has achieved significant milestones, including collaborations with top-tier pharmaceutical firms and healthcare organisations. Pharmacoevidence's innovative approach to pharmacoeconomic modelling and its comprehensive suite of services position it as a trusted partner in the evolving landscape of health economics, making it a notable player in the global market.
DitchCarbon Score
How does Pharmacoevidence Private's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmacoevidence Private's score of 12 is lower than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmacoevidence Private's reported carbon emissions
Pharmacoevidence Private Limited, headquartered in India, has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. Although no specific emissions data is currently available, the company has established targets through the Science Based Targets initiative (SBTi). Pharmacoevidence commits to reducing its Scope 1 and Scope 2 emissions by 42% by the year 2030, using 2023 as the baseline year. This target aligns with the necessary reductions to limit global warming to 1.5°C, reflecting the company's dedication to climate action. Additionally, the company plans to measure and address its Scope 3 emissions, further enhancing its sustainability efforts. These targets were approved via a streamlined validation route specifically designed for small and medium-sized enterprises (SMEs), underscoring Pharmacoevidence's proactive approach to environmental responsibility. The company is on track to implement these initiatives, contributing to a more sustainable future in the professional services sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmacoevidence Private is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
